These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 19961222

  • 1. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
    Mahalingam AK, Axelsson L, Ekegren JK, Wannberg J, Kihlström J, Unge T, Wallberg H, Samuelsson B, Larhed M, Hallberg A.
    J Med Chem; 2010 Jan 28; 53(2):607-15. PubMed ID: 19961222
    [Abstract] [Full Text] [Related]

  • 2. Microwave-accelerated synthesis of P1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold.
    Ekegren JK, Ginman N, Johansson A, Wallberg H, Larhed M, Samuelsson B, Unge T, Hallberg A.
    J Med Chem; 2006 Mar 09; 49(5):1828-32. PubMed ID: 16509598
    [Abstract] [Full Text] [Related]

  • 3. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
    Ekegren JK, Unge T, Safa MZ, Wallberg H, Samuelsson B, Hallberg A.
    J Med Chem; 2005 Dec 15; 48(25):8098-102. PubMed ID: 16335934
    [Abstract] [Full Text] [Related]

  • 4. Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.
    Wu X, Ohrngren P, Ekegren JK, Unge J, Unge T, Wallberg H, Samuelsson B, Hallberg A, Larhed M.
    J Med Chem; 2008 Feb 28; 51(4):1053-7. PubMed ID: 18215014
    [Abstract] [Full Text] [Related]

  • 5. Synthesis of P1'-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol.
    De Rosa M, Unge J, Motwani HV, Rosenquist Å, Vrang L, Wallberg H, Larhed M.
    J Med Chem; 2014 Aug 14; 57(15):6444-57. PubMed ID: 25054811
    [Abstract] [Full Text] [Related]

  • 6. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A, Reddy GS, Cao H, Anjum SG, Nalam MN, Schiffer CA, Rana TM.
    J Med Chem; 2006 Dec 14; 49(25):7342-56. PubMed ID: 17149864
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
    Smith AB, Cantin LD, Pasternak A, Guise-Zawacki L, Yao W, Charnley AK, Barbosa J, Sprengeler PA, Hirschmann R, Munshi S, Olsen DB, Schleif WA, Kuo LC.
    J Med Chem; 2003 May 08; 46(10):1831-44. PubMed ID: 12723947
    [Abstract] [Full Text] [Related]

  • 8. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK, Ala P, Woerner FJ, Chang CH, Garber SS, Anton ED, Bacheler LT.
    J Med Chem; 1997 Jan 17; 40(2):181-91. PubMed ID: 9003516
    [Abstract] [Full Text] [Related]

  • 9. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
    Wannberg J, Sabnis YA, Vrang L, Samuelsson B, Karlén A, Hallberg A, Larhed M.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5303-15. PubMed ID: 16621572
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.
    Melnick M, Reich SH, Lewis KK, Mitchell LJ, Nguyen D, Trippe AJ, Dawson H, Davies JF, Appelt K, Wu BW, Musick L, Gehlhaar DK, Webber S, Shetty B, Kosa M, Kahil D, Andrada D.
    J Med Chem; 1996 Jul 05; 39(14):2795-811. PubMed ID: 8709110
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB, Charnley AK, Harada H, Beiger JJ, Cantin LD, Kenesky CS, Hirschmann R, Munshi S, Olsen DB, Stahlhut MW, Schleif WA, Kuo LC.
    Bioorg Med Chem Lett; 2006 Feb 15; 16(4):859-63. PubMed ID: 16298527
    [Abstract] [Full Text] [Related]

  • 16. Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors.
    Joshi A, Véron JB, Unge J, Rosenquist Å, Wallberg H, Samuelsson B, Hallberg A, Larhed M.
    J Med Chem; 2013 Nov 27; 56(22):8999-9007. PubMed ID: 24160253
    [Abstract] [Full Text] [Related]

  • 17. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF, Furfine ES, Hanlon MH, Hazen RJ, Ray JA, Robinson L, Samano V, Spaltenstein A.
    Bioorg Med Chem Lett; 2004 Feb 23; 14(4):959-63. PubMed ID: 15013001
    [Abstract] [Full Text] [Related]

  • 18. Variations of the P2 group in HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
    Ekegren JK, Gising J, Wallberg H, Larhed M, Samuelsson B, Hallberg A.
    Org Biomol Chem; 2006 Aug 21; 4(16):3040-3. PubMed ID: 16886068
    [Abstract] [Full Text] [Related]

  • 19. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
    Alterman M, Björsne M, Mühlman A, Classon B, Kvarnström I, Danielson H, Markgren PO, Nillroth U, Unge T, Hallberg A, Samuelsson B.
    J Med Chem; 1998 Sep 24; 41(20):3782-92. PubMed ID: 9748353
    [Abstract] [Full Text] [Related]

  • 20. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN, Shepherd TA, Baxter AJ, Burgess J, Hatch SD, Lubbehusen P, Wiskerchen M, Muesing MA.
    J Med Chem; 1996 Jan 05; 39(1):96-108. PubMed ID: 8568831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.